The phosphoprotein NS5A of hepatitis C virus has recently been suggested to control PKR protein kinase for resistance to interferon. To investigate other functions of NS5A, studies were initiated on the regulation of transcription of important cellular genes and of cell growth by this protein. The results suggested that NS5A protein represses transcription of the cell cycle regulatory gene p21 WAF1 , while it activates the human proliferating cell nuclear antigen gene in murine fibroblasts and human hepatoma cells. Furthermore, introduction of NS5A into murine fibroblasts (NIH3T3) promoted anchorage-independent growth and tumour formation in nude mice. Thus, NS5A appears to exhibit a role in cell growth regulation.
Hepatitis C virus (HCV) is an important cause of morbidity and mortality worldwide, causing a spectrum of liver disease ranging from an asymptomatic carrier state to end-stage liver disease. The HCV genome contains a linear, positive-strand RNA molecule of " 9500 nucleotides, with variability apparent in the viral genome and several genotypes described (Choo et al., 1989 ; Chamberlain et al., 1997 ; Simmonds, 1998) . Information on the mechanism of HCV replication at the molecular level has so far depended upon the expression of its partial or entire genome and comparative analysis with genomes of distantly related flaviviruses or pestiviruses (Zanotto et al., 1996 ; Clarke, 1997) . The HCV genome encodes a single polyprotein precursor that is cleaved by both host and viral proteases to generate at least ten individual proteins. The putative structural proteins (Core, E1 and E2\p7) are located in the amino-terminal one-third of the polyprotein and the nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B) are located in the carboxy-terminal two-thirds of the polyprotein. NS5A protein is generated as a mature product by the action of NS3 protease in conjunction with NS4A (Tanji et al., 1995) . NS5A exists as phosphoproteins (p56 and p58) and the Author for correspondence : Ratna Ray (at the Department of Pathology). Fax j1 314 771 3816. e-mail rayrb!slu.edu degree of phosphorylation accounts for the differences in size (Kaneko et al., 1994) . Although the phosphorylation of NS5A occurs predominantly on serine residues, a low level of phosphorylation on threonine residues has also been observed (Reed et al., 1997) . Apart from the probable role of NS5A in the replication cycle, it may be a critical factor in determining the susceptibility of the virus to interferon (Enomoto et al., 1995) .
NS5A protein localizes in the nuclear periplasmic membrane fraction (Tanji et al., 1995) . Recent studies have suggested that two-thirds of the carboxy terminus of HCV NS5A protein functions as a transcriptional activator in yeast and mammalian cells in the context of the GAL4 system (Kato et al., 1997 ; Tanimoto et al., 1997) . However, the full-length NS5A protein does not exert an effect in a similar experimental system. This interesting information led to our investigation of the effect of NS5A on the critical components [p21 WAF" , p53 and proliferating cell nuclear antigen (PCNA)] involved in cell cycle regulation and its role in murine fibroblast growth regulation.
Cell cycle progression is driven by the sequential activation of cyclin-dependent kinases (CDKs), which are subject to regulation by positive (cyclins) and negative (CDK-inhibitory proteins) effectors (Morgan, 1995) . One such effector is the universal CDK inhibitor p21 WAF" (Harper et al., 1993 ; Yang et al., 1995) . p21 may participate in apoptosis and increased p21 expression correlates with enhanced cell death under certain conditions (el-Deiry et al., 1993 ; Sheikh et al., 1995) . The p21 protein binds to and inhibits the activity of CDKs by preventing the phosphorylation of critical CDK substrates and blocking cell cycle progression (Harper et al., 1993 ; Xiong et al., 1993) . To determine the role of HCV NS5A protein in p21 regulation, a transient transfection assay was performed as described previously (Ray et al., 1998) . NIH Swiss mouse embryo fibroblasts (NIH3T3) and human hepatoma (HepG2) cells were transfected with 4 µg reporter construct (WWP-luc ; p21 promoter linked to luciferase gene) and different amounts of the effector construct (NS5A from HCV genotype 1a, under the control of a cytomegalovirus early promoter) or 4 µg pcDNA3 vector control by using a standard lipofectamine protocol (Life Technologies). Transfection efficiencies were normalized to an internal β-galactosidase control and luciferase activity was determined. Results from the luciferase assay with HepG2 or NIH3T3 cells suggested that the NS5A protein inhibits p21 promoter activity in a dose-dependent manner ( Fig. 1) . A similar analysis with two other unrelated cellular genes, MBP-1 (Ray & Miller, 1991) and PTEN (Li et al., 1997) , cloned into pcDNA3 vector did not suggest a detectable modulation of the p21 promoter activity (data not shown). Hepatocellular carcinoma accounts for over 90 % of primary liver cancers and may progress through inactivation of the p53 gene (Hsu et al., 1991) . p53 tumour suppressor protein regulates transcription of p21 and participates in the effects of p53 (el-Deiry et al., 1993) . Induction of p21 also occurs via p53-independent pathways (Liu et al., 1996 ; Michieli et al., 1994) . Since HCV appears to play a role in the development of hepatocellular carcinoma, the effect of HCV NS5A protein on the human p53 promoter was examined by an in vitro transient transfection of NIH3T3 cells as described previously (Ray et al., 1997) . The result suggested that NS5A does not have a detectable regulatory role in transcription from the p53 promoter (data not shown). On the other hand, the HCV core gene cloned into pcDNA3 vector, when used as a positive control, down-regulated the p53 promoter as previously observed (Ray et al., 1997) .
PCNA, a DNA damage-inducible protein, plays a crucial role as an integral component of the eukaryotic DNA replication machinery in normal cellular growth and differentiation (Bravo et al., 1987 ; Stillman, 1989 ). This gene is required for cell growth and cell cycle progression in mammalian cells and is found in quaternary complexes containing cyclins, CDKs and the inhibitor p21 (Xiong et al., 1993) . To investigate whether NS5A has an effect on the PCNA promoter, an in vitro transient transfection assay was performed by using plasmids containing HCV NS5A as an effector and the PCNA-CAT construct as a reporter gene (Morris & Mathews, 1990) . NIH3T3 or HepG2 cells were cotransfected with different (Reed et al., 1997) . A secondary antibody (antirabbit Ig) coupled to horseradish peroxidase was used for detection of protein bands by chemiluminescence (Amersham). The position of NS5A was ascertained from migration of standard molecular mass markers (Life Technologies).
amounts of the effector DNA and 2 µg reporter plasmids and the CAT assay was performed as previously described (Ray et al., 1997) . Transfection efficiencies were normalized to an internal β-galactosidase control. Results from this study suggested that NS5A transactivates the PCNA promoter in a dose-dependent manner (Fig. 2 a) . A similar observation was also noted following transfection of HepG2 cells, suggesting that transactivation of the PCNA promoter by NS5A protein is independent of the cell type used. To determine whether modulation of the cellular promoter was due to the different levels of NS5A expression, NIH3T3 cells transfected with increasing amounts of NS5A plasmid DNA were subjected to Western blot analysis with rabbit antiserum to NS5A as the primary antibody (Reed et al., 1997) . Results from this experiment exhibited NS5A expression in a dose-dependent BBIA manner (Fig. 2 b) . To examine whether NS5A exerted a similar effect on a stably integrated PCNA gene, studies were conducted in stable transfectants expressing a cellular CAT gene construct during differentiation in NIH3T3 cells, as described by Kitabayashi et al. (1992) . NIH3T3 cells were transfected with PCNA-CAT and pcDNA3 plasmid DNAs at a 10 : 1 ratio. Cells were selected in the presence of G418 (500 µg\ml) for 3 weeks and stable transfectants of NIH3T3 with PCNA-CAT were established. A pool of G418-resistant cells were transfected with HCV NS5A and the CAT assay was performed. Results from this study suggested that NS5A enhances the activity of the stably integrated PCNA-CAT in a dose-dependent manner (Fig. 2 a) , similar to the results observed in transient transfection experiments.
In many cases, viral proteins may function normally in signalling pathways affecting cell growth or cell death. In addition to the observed trans-regulatory role, the NS5A protein exerts a direct repression on PKR activity (Gale et al., 1997) , which in turn may induce transformation (Koromilas et al., 1992) . To examine whether NS5A protein has a role in cell growth regulation, murine fibroblasts (NIH3T3) were transfected with 2 µg HCV NS5A expression vector or 2 µg pcDNA3 (vector control). Transfected cells were split after 48 h at a ratio of 1 : 9 and incubated with G418 (500 µg\ml) for selection of drug-resistant colonies. Three weeks after transfection, one set of plates was fixed and stained with Giemsa to count the transformed foci (Ray, 1995) . NIH3T3 cells transfected with vector DNA (NIH3T3neo) exhibited 90p22 colonies, whereas NS5A-transfected cells (NIH3T3NS5A) exhibited 220p17 colonies (means from three independent experiments).
Phenotypic characteristics of NS5A-or vector-transfected pooled NIH3T3 cells were analysed for soft agar colonyforming ability, as previously described (Ray et al., 1996) . Each cell type was tested in triplicate for growth on soft agar for reproducibility. Results indicated that NIH3T3NS5A cells exhibited growth in soft agar at a high frequency (69 %) within 2n5 weeks, whereas NIH3T3neo control cells failed to show significant growth (3 %) under similar conditions. The transformed phenotype of the NIH3T3NS5A cells was evaluated further for tumour formation in athymic nude mice. Experimental NIH3T3NS5A cells or control NIH3T3neo cells (5i10') were injected subcutaneously into nude mice. At 2 weeks after injection, tumours developed in all mice (6\6) inoculated with the NIH3T3NS5A cells. However, none of the mice (0\4) inoculated with negative-control cells exhibited any detectable tumour formation. One control mouse initially showed a small nodule, which did not grow further following observation up to 4 weeks after the injection. Tumours from NIH3T3NS5A cells grew to a large size ( 2 cm) within 3 weeks and the mice became progressively ill. At this time, the experimental animals were sacrificed and the tumours were removed.
NS5A expression in cells at the mRNA level was analysed Fig. 3 . Expression of NS5A and endogenous PCNA, p53 and p21 proteins. Equal amounts of protein from controls (NIH3T3neo) and NS5A stable transfectants (NIH3T3NS5A) were loaded in each lane for Western blot analysis with rabbit antisera to NS5A (Reed et al., 1997) and p21 (Santa Cruz) and murine monoclonal antibodies to PCNA and p53 (Santa Cruz). A secondary antibody (anti-rabbit or anti-mouse Ig) coupled to horseradish peroxidase was used for detection of the respective proteins by chemiluminescence. The position of the specific protein bands in the blot was also verified from migration of standard protein molecular mass markers. The nitrocellulose blot was overexposed for detection of p53.
Intensities of the protein bands on the X-ray film were analysed by a scanner (Molecular Dynamics personal densitometer).
by RT-PCR. Total RNA was extracted (Chomczynski & Sacchi, 1987) from the controls, NS5A transfectants and tumours for amplification of the NS5A sequence by RT-PCR by using specific primers (sense, 5h GGACGATGAGGAT-CGTCGG 3h and antisense, 5h TGGCTAGCCGAGGAGC-TGG 3h). A typical amplification of an NS5A-specific, 490 bp product from experimental samples was observed (data not shown). Furthermore, the endogenous protein expression of p21, PCNA and p53 in control NIH3T3neo and stable NIH3T3NS5A transfectants was investigated by Western blot analysis. Results suggested 5-fold lower expression of p21 and 3-fold higher expression of PCNA in the NS5A-expressing stable cell lines (Fig. 3) . On the other hand, the p53 expression level remained similar in vector-transfected and NS5A-expressing cells. A higher dose of NS5A plasmid (4 µg) downregulated p21 promoter activity significantly in an in vitro transient expression assay (Fig. 1) . On the other hand, the p21 expression level in NIH3T3NS5A stable transfectants was lower (Fig. 3) , but was not abolished completely. This discrepancy is due to the nature of the two different experiments.
BBIB
We have demonstrated that the NS5A protein of HCV differentially modulates transcription of p21 WAF" and PCNA and promotes murine fibroblast cell growth to a tumorigenic phenotype. A recent report demonstrated that PKR interacts with NS5A in both mammalian and yeast cells (Gale et al., 1998) . Whether PKR plays a role in the modulation of p21 and PCNA expression, or how these promoter activities are regulated by NS5A, is not known. Since the predicted amino acid sequence of NS5A does not include a known DNAbinding motif, this protein may act through a cellular factor(s) for the regulation of cell growth. Alternatively, PKR may serve as a bridging factor with NS5A and thereby exert its regulatory activity. We have observed different effects of NS5A on cellular promoters and to our knowledge there is no report that PKR modulates transcription of any of the genes we have tested. Thus, it appears that NS5A regulates transcription of these cellular genes either by direct interaction with a general transcriptional factor(s) or through a cofactor. Furthermore, both the PCNA and p53 promoters when linked to the CAT reporter gene exhibited distinct CAT activity upon cotransfection with NS5A in our transient transfection assay. Thus, PKR does not appear to exert an effect on the regulation of translation in our experimental system, otherwise a similar effect on CAT expression should have been observed. Viral genes can override cellular control mechanisms that in untransformed cells regulate cell cycle progression in response to various antiproliferative signals. HCV often causes persistent infection and a ' silent ' disease. There is no evidence that the HCV genome integrates in infected cells. In addition to NS5A, two other HCV proteins (core and NS3) promote cell growth (Sakamuro et al., 1995 ; Chang et al., 1998 ; Ray et al., 1996) . Cell cycle progression is inhibited in productively infected cells and most infected cells are eventually killed as the virus completes its replication cycle. However, in persistently infected cells, as in the case of HCV, defective viral genomes may arise from mutations. If cell growth is induced by a nonproductive infection, the continued presence of viral gene products would be likely to be detrimental for host cells, as appears to be the case with the silent disease caused by HCV. The biological role of these individual viral proteins in HCVmediated pathogenesis remains to be elucidated.
